Resumen de: US2023086390A1

Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of antiviral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.

Resumen de: US2023089605A1

In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to a therapeutic treatment or prevention of viral infections such as, for example, COVID-19. In one aspect, the therapeutic treatment combines the administration of doxycycline and/or chemically-modified tetracyclines with resveratrol and ivermectin. In another aspect, the disclosed treatment offers anti-inflammatory effects, can combat the effects of reactive oxygen species, and can inhibit the activity of matrix metalloproteinase enzymes; these combined effects may, in some aspects, be useful in preventing or mediating the effects of the cytokine storm that is associated with poor COVID-19 outcomes including death. In some aspects, dosages of the treatment can be modified to account for COVID-19 comorbidities including, but not limited to, such conditions as diabetes or hypertension.

Resumen de: US2023087473A1

A suspo-emulsion dosage form of anthelmintic drug such as Ivermectin or niclosamide with essential oils was proposed to be used for administration to the nasal cavity and lungs. The suspo-emulsion formulation is to be administered using a suitable medical device. The composition may be used to treat or prevent viral infections such as Covid-19.

Resumen de: US2023090551A1

A composition for detecting SARS-CoV-2 is provided; moreover, a kit including the composition, the use of the kit, and a method for detecting SARS-CoV-2 are also provided.

Resumen de: US2023090517A1

A composite quaternary ammonium salt disinfectant includes a double long-chain quaternary ammonium salt, two single long-chain quaternary ammonium salts, a synergist isothiazolinone, a nonionic surfactant fatty alcohol polyvinyl ether, and water, wherein the double long-chain quaternary ammonium salt is dialkyl dimethyl ammonium chloride with dialkyl being two independent alkyl groups with a chain length of C8-C18, and the two single-chain quaternary ammonium salts are alkyl dimethyl benzyl ammonium chloride with an alkyl chain length of C8-C18 and alkyl dimethyl ethyl benzyl ammonium chloride with an alkyl chain length of C8-C18, respectively. The composite quaternary ammonium salt disinfectant has a synergistic effect among its components, which greatly improves the capacity of resisting interferences by hard water and organics; and can kill not only bacterial propagules, lipophilic viruses (enveloped viruses, such as novel coronavirus) and fungi, but also hydrophilic viruses (non-enveloped viruses).

Resumen de: US2023090502A1

The present invention is directed towards methods, compositions and kits for testing SARS-CO-V2 virus in a sample. The methods determine the presence of a viral 3CL protease by contacting the sample with a peptide compound capable of being cleaved by the protease to form peptide compound fragments. Detection of a peptide compound fragment confirms the presence of the virus.

Resumen de: US2023091224A1

A method, system, and/or apparatus for automatically monitoring for possible infection or other physical health concerns, such as from Covid-19. The method or implementing software application uses or relies upon location information available on the mobile device from any source, such as cell phone usage and/or other device applications. The method and system automatically uses and/or learns user location and activity patterns and determines and infection risk or illness-based deviation that can be communicated as a warning to community members.

Resumen de: US2023091497A1

Provided herein are methods for reducing risk of severe symptoms and outcomes associated with Coronavirus Disease 2019 (COVID-19) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection by measuring levels of interleukin 6 (IL-6), IL-8, IL-22, and serum ferritin in a subject. Also provided are methods for treating a subject exposed to or at elevated risk of expose to SARS-CoV-2 based on levels of IL-6, IL-8, IL-22, and ferritin in the serum of the subject.

Resumen de: WO2021228750A1

The present invention relates to the use of organic and highly water-soluble compatible solutes or of a solute mixture, preferably in the form of an inhalable composition suitable for oropharyngeal, nasal and intravenous administration, in the prevention or treatment of diseases caused by ss(+)RNA viruses of the Coronaviridae family, preferably diseases caused by SARS-CoV-1, SARS-CoV-2, MERS-CoV, HCoV-HKU1, HCoV-OC43, HCoV-NL63 and/or HCoV-229E. Particularly suitable solutes according to the invention are ectoine and its derivatives, glycoin, mannosylglycerate (firoin) and mannosylglyceramide (firoin-A), which, by virtue of their strong water-binding capacity, reduce the binding of the viruses to the receptors of the host cell in the transitional epithelium, e.g. eye, in the inner epithelium, e.g. lung, and in the endothelium and thus reduce or prevent the reproduction of the virus. According to the invention, prevention is made possible by sputum and breath which are less infectious, and treatment and rehabilitation of the affected tissues are made possible by the membrane-protecting properties of the compatible solutes according to the invention.

Resumen de: WO2021229450A1

RNA replicons encoding coronavirus S proteins, in particular SARS-CoV-2 S proteins, are described. Also described are pharmaceutical compositions and uses of the RNA replicons.

Resumen de: WO2021231044A1

According to various embodiments, a machine-learning based system for coronavirus detection is disclosed. The system includes one or more processors configured to interact with a plurality of wearable medical sensors (WMSs). The processors are configured to receive physiological data from the WMSs and questionnaire data from a user interface. The processors are further configured to train at least one neural network based on raw physiological data and questionnaire data augmented with synthetic data and subjected to a grow-and-prune paradigm to generate at least one coronavirus inference model. The processors are also configured to output a coronavirus-based decision by inputting the received physiological data and questionnaire data into the generated coronavirus inference model.

Resumen de: WO2021231570A1

Provided herein are methods for the treatment and prevention of viral infections (e.g., coronavirus infections (e.g., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), etc.), etc.) and diseases (e.g., Coronavirus disease 2019 (COVID-19)) associated therewith by the administration of cysteamine or derivatives thereof to a subject.

Resumen de: WO2021231929A1

Present application relates to a strategy for compensating for transesterification degradation of lipid-encapsulated RNA, such as mRNA-LNP, in liquid formulations for high-volume distribution. This involves determining the rate of degradation of the encapsulated RNA and calculating an appropriate overage relative to the intended dose. Alternatively, a higher dose of the RNA may be administered to compensate for loss of effective RNA or the RNA may be formulated in higher purity in anticipation of degradation. The strategy provides a balance between supplying effective and safe products and the need for costly manufacturing processes or transportation hurdles, such as cold-chain supply.

Resumen de: WO2021232048A1

Embodiments of the disclosure includes methods of producing viral-specific therapy (VST) cells specific for the SARS-CoV-2 virus and uses of the cells. The methods may utilized peptide mixtures and stimulation of mononuclear cells using particular cytokine cocktails. The cells may also be genetically modified to lack expression of one or more endogenous genes, including one or more genes that renders the cells more effective and/or able to withstand deleterious conditions, such as the presence of glucocorticoids.

Resumen de: WO2021231923A1

Provided herein are recombinant polypeptides comprising a SARS-CoV-2 S1 protein binding domain polypeptide and a GM-CSF polypeptide, polynucleotide sequences encoding the same, virus-like particles comprising the same, and methods for using these compositions for the treatment of a SARS-CoV-2 infection in a subject, and for detection of a SARS-CoV-2 antibodies in a subject.

Resumen de: EP4151232A1

An active or inactivated recombinant vaccine against COVID-19 is described that comprises a Newcastle disease viral vector and a pharmaceutically acceptable carrier, adjuvant and/or excipient, characterized in that the viral vector is a virus capable of generating a cellular immune response that has a SARS-CoV-2 exogenous nucleotide sequence inserted.

Resumen de: EP4151211A1

Provided is a novel inhalant as a therapeutic agent for COVID-19. The present invention relates to an inhalant containing cepharanthine.

Resumen de: WO2021226729A1

The invention provides a set of VHH single-domain antibodies or nanoantibodies against SARS-CoV-2 (SEQ ID no. 1-44) and to the use thereof to detect, diagnose and neutralise the virus in vitro and in vivo.

Resumen de: WO2021231651A2

Antibodies, including single-domain antibodies, that bind to SARS-CoV2 virus and methods of treatment using single-domain antibodies that bind to SARS-CoV2 virus are provided.

Resumen de: EP4151214A1

The invention relates to the use of rimegepant or a pharmaceutically acceptable salt thereof for use in the treatment of infection of human coronavirus, namely SARS-CoV-2 and its variants (e.g. alpha, beta, gamma, delta, omicron, and others).

Resumen de: EP4151730A1

The present invention relates to specific reverse micelle system of the invention which allows the administration and intracellular delivery of unmodified oligonucleotide, such as siRNA, targeting one or more genes of the SARS-CoV-2 virus. The reverse micelle system of the invention is thus particularly useful for the treatment of COVID-19.

Resumen de: WO2021229519A1

The present invention relates to sterols for use in the prevention and/or in the treatment of a viral infection caused by SARS-CoV-2 (COVID-19).

Resumen de: WO2021229430A1

The present invention describes a novel process for the production of lysozyme HCl from hen egg white (HEW) with high chemical purity, and the use of said antiviral agent against SARS-CoV-2, optionally combined with other antivirals and/or immunosuppressants and ovotransferrin.

Resumen de: WO2021228853A1

The present invention relates to a vaccine composition and its use against a Severe acute respiratory syndrome-related coronavirus.

Resumen de: US2023078211A1

A decontamination system includes a housing having at least one inner surface defining a chamber. An irradiation system supplies ultraviolet germicidal irradiation (UVGI) to the chamber at a level effective to at least one of inactivate SARS-CoV-2 or inactivate at least 90% single-stranded RNA viruses present on an object positioned in the chamber in less than about 2 minutes.